Pisit Pitukcheewanont

Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

Erik A. Imel, Francis H. Glorieux, Michael P. Whyte et al. · The Lancet · 2019 · 347 citations · Full text

X-linked Hypophosphataemia, Pediatric Hematology, Hematology +2

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

Karl Insogna, Karine Briot, Erik A. Imel et al. · Journal of Bone and Mineral Research · 2018 · 329 citations · Full text

Sclerostin, Human Growth, Immunology +21

Increased Body Weight and Decreased Radial Cross-Sectional Dimensions in Girls with Forearm Fractures

David L. Skaggs, M. Luiza Loro, Pisit Pitukcheewanont et al. · Journal of Bone and Mineral Research · 2001 · 234 citations · Full text

Sensitivity of Fibroblast Growth Factor 23 Measurements in Tumor-Induced Osteomalacia

Erik A. Imel, Munro Peacock, Pisit Pitukcheewanont et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 226 citations

A Pilot Study of the Continuous Glucose Monitoring System

Francine Kaufman, Leena Caroline Gibson, Mary Halvorson et al. · Diabetes Care · 2001 · 221 citations · Full text